NRPH

New River (NRPH)

New River Pharmaceuticals (MM)

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NRPH

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2007/04/19	05 : 41	PR Newswire (US)	HealthShares(TM) Announces Changes to the HealthShares(TM) Neuroscience and Composite Indices	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2007/04/03	22 : 00	PR Newswire (US)	New River Pharmaceuticals Inc. Announces Convertibility of 3.50% Convertible Subordinated Notes Due 2013	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2007/03/19	23 : 00	PR Newswire (US)	New River Announces Expiration of Hart-Scott-Rodino Waiting Period	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2007/03/14	08 : 30	PR Newswire (US)	New River Pharmaceuticals Announces Year-End Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2007/02/24	07 : 07	PR Newswire (US)	Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug VYVANSE(TM) (lisdexamfetamine	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2007/02/20	20 : 00	PR Newswire (US)	New River Pharmaceuticals to be Acquired by Shire plc for $64 per Share	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2007/02/06	00 : 18	PR Newswire (US)	New River Pharmaceuticals to Present at 2007 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Conference	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2007/01/26	05 : 01	PR Newswire (US)	James Shaffer Joins New River Pharmaceuticals as Vice President, Sales and Marketing	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/12/22	13 : 34	PR Newswire (US)	New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/12/22	13 : 34	PR Newswire (US)	New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/11/08	07 : 22	PR Newswire (US)	New River Pharmaceuticals Announces Third Quarter 2006 Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/10/30	23 : 00	PR Newswire (US)	Interim Results of a Phase III Trial of Lisdexamfetamine Dimesylate (NRP104/LDX) in ADHD Presented at Major Scientific Meeting	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/10/13	22 : 45	PR Newswire (US)	New River Pharmaceuticals Conducts End-of-Phase II Meeting with FDA for NRP290	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/10/07	10 : 25	PR Newswire (US)	FDA Issues Approvable Letter for NRP104 (lisdexamfetamine dimesylate) for the Treatment of ADHD	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/10/07	10 : 23	PR Newswire (US)	New River Pharmaceuticals Inc. Receives Approvable Letter for NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/10/04	06 : 20	PR Newswire (US)	Dr. Garen Manvelian Joins New River Pharmaceuticals as Chief Medical Officer	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/09/13	04 : 00	PR Newswire (US)	New River Pharmaceuticals Inc. Meets Enrollment in NRP104 Adult Phase III Study	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/09/09	06 : 38	PR Newswire (US)	New River Pharmaceuticals to Present at the Bear Stearns 19th Annual Healthcare Conference	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/08/18	07 : 03	PR Newswire (US)	New River Pharmaceuticals Names Dr. Samir Roy Vice President, Formulation and Manufacturing	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/08/09	06 : 46	PR Newswire (US)	New River Pharmaceuticals Announces Second Quarter 2006 Results	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/07/26	05 : 58	PR Newswire (US)	New River Pharmaceuticals Announces Exercise of Co-Promotion Option in the U.S. for NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/07/26	01 : 57	PR Newswire (US)	New River Pharmaceuticals Closes Sale of $135,000,000 Convertible Subordinated Notes	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/07/24	22 : 41	Business Wire	AMRI Announces Long-Term Manufacturing Agreement with New River Pharmaceuticals	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/07/20	10 : 06	PR Newswire (US)	New River Pharmaceuticals Prices $125 Million Convertible Subordinated Notes; Company to Repurchase Up to $51 million in Common	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/07/19	06 : 26	PR Newswire (US)	New River Pharmaceuticals Announces Proposal to Offer $125 Million Convertible Subordinated Notes; Company to Repurchase up to	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/06/30	23 : 31	PR Newswire (US)	New River Pharmaceuticals Announces Filing of Investigational New Drug Application for NRP409	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/06/24	01 : 52	PR Newswire (US)	New River Pharmaceuticals to Host Conference Call on A01, A02 and A03 Clinical Abuse Liability Studies of NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/06/21	06 : 30	PR Newswire (US)	New River Pharmaceuticals Provides Detail on A02 Clinical Abuse Liability Study of NRP104	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/06/19	06 : 45	PR Newswire (US)	New River Pharmaceuticals Provides Detail on A01 Clinical Abuse Liability Study and Announces Results from A03 Study	NASDAQ:NRPH	New River Pharmaceuticals (MM)
2006/06/14	22 : 01	PR Newswire (US)	New River Pharmaceuticals to Present Results from NRP104 Abuse Liability Studies	NASDAQ:NRPH	New River Pharmaceuticals (MM)